
-
The music industry is battling AI -- with limited success
-
New app hopes to empower artists against AI
-
Haiti jazz festival is rare respite for violence-racked capital
-
Johnson satisfied after opening Grand Slam series event
-
China would have agreed TikTok deal if not for US tariffs: Trump
-
Market panic mounts as world scrambles to temper Trump tariffs
-
Harman keeps calm in the winds to clinch Texas Open
-
Doncic scores 30 as Lakers rout Thunder
-
Qualifier Brooksby stuns Tiafoe to win first ATP title
-
McLaughlin-Levrone seals Grand Slam jackpot with 400m victory
-
Juventus miss out on Serie A's top four with Roma draw
-
Marseille, Strasbourg win in Ligue 1 to close in on Champions League
-
Pegula wins WTA Charleston after Kenin collapse
-
Second US child dies of measles, almost 650 ill: officials
-
Thousands attend funeral of legendary Malian musician Amadou
-
Gaza rescuers say Israeli strikes kill 44
-
Alcaraz admits pressure to take Sinner's number one ranking 'killed' him
-
US storms, 'devastating' flooding death toll climbs to 17
-
Ovechkin achieves the 'impossible'
-
Comeback man Siraj's 4-17 helps Gujarat to hat-trick of IPL wins
-
Ovechkin scores 895th goal to clinch all-time NHL record
-
No 'killer instinct' as Man Utd, Man City play out derby stalemate
-
Siraj's 4-17 helps Gujarat to hat-trick of IPL wins
-
Man City held by Man Utd in derby stalemate
-
'Minecraft Movie' strikes gold to dominate N.America box office
-
World scrambles to temper Trump tariffs as market fears mount
-
Strasbourg close in on Champions League with Ligue 1 win at Reims
-
Toulouse overpower Sale to reach rugby Champions Cup last eight
-
Slot shocked by sloppy Liverpool errors in Fulham defeat
-
Zelensky slams US lack of response to Putin truce rejection
-
Juric urges Southampton to learn from record-setting relegation
-
Italian director Moretti leaves hospital after heart attack
-
Chelsea's 'unfair' schedule to blame for Palmer axe: Maresca
-
Barrios grabs Atletico late Liga win at Sevilla
-
Le Pen slams 'witch hunt', vows not to give up at Paris rally
-
Liverpool's rare loss delays title march, Southampton relegated
-
World scrambles to temper Trump tariffs: White House
-
Southampton relegated from Premier League in record time
-
Fulham end Liverpool unbeaten league run to delay title party
-
Torrential rains kill dozens in DR Congo capital
-
Pogacar wins Van der Poel duel at cycling's Tour of Flanders
-
Djokovic plays down Monte Carlo hopes after eye infection
-
Israel targets Hezbollah in south Lebanon as US envoy visits
-
Bumrah 'available' for Mumbai's IPL clash with Bengaluru
-
Bordeaux book Champions Cup quarter-final with victory over Ulster
-
Israel's Netanyahu ends Hungary visit, heads to US
-
Fiji and New Zealand seal sevens wins in Singapore
-
Le Pen invokes Martin Luther King ahead of far-right Paris rally
-
Zelensky says attacks 'increasing' as 2 killed in missile and drone attacks
-
Vietnam seeks US tariff delay as economic growth slows in first quarter
RBGPF | 100% | 69.02 | $ | |
NGG | -5.25% | 65.93 | $ | |
VOD | -10.24% | 8.5 | $ | |
RYCEF | -18.79% | 8.25 | $ | |
GSK | -6.79% | 36.53 | $ | |
CMSC | 0.13% | 22.29 | $ | |
BTI | -5.17% | 39.86 | $ | |
AZN | -7.98% | 68.46 | $ | |
RIO | -6.88% | 54.67 | $ | |
RELX | -6.81% | 48.16 | $ | |
BCC | 0.85% | 95.44 | $ | |
JRI | -7.19% | 11.96 | $ | |
SCS | -0.56% | 10.68 | $ | |
BCE | 0.22% | 22.71 | $ | |
CMSD | 0.7% | 22.83 | $ | |
BP | -10.43% | 28.38 | $ |

US approves new drug to treat Alzheimer's
The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in the early stages of Alzheimer's disease.
The FDA approval of the drug, Leqembi, also known as lecanemab, came just days after the agency was harshly criticized in a congressional report for its green-lighting of another Alzheimer's drug, Aduhelm.
And it was granted despite trial results showing the monoclonal antibody treatment carries risks of brain swelling and bleeding.
Both drugs were approved by the FDA through an accelerated process that allows the US regulatory agency to fast-track approval of drugs for serious conditions where there is an unmet medical need.
Leqembi and Aduhelm, which were both jointly developed by Japan's Eisai and Biogen of the United States, "represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease," the FDA said in a statement.
"Alzheimer's disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones," Billy Dunn of the FDA's Center for Drug Evaluation and Research said in a statement.
Leqembi is "the latest therapy to target and affect the underlying disease process of Alzheimer's, instead of only treating the symptoms of the disease," Dunn said.
Preliminary data from a trial of Leqembi was released in September and found it slowed cognitive decline in Alzheimer's patients by 27 percent.
The phase three trial involved nearly 1,800 people, divided between those given the drug and given a placebo, and ran over 18 months.
The complete trial data, published in the New England Journal of Medicine, fleshed out the findings but also raised concern about the incidence of "adverse effects" including brain bleeds and swelling.
The results showed that 17.3 percent of patients administered the drug experienced brain bleeds, compared with nine percent of those receiving a placebo.
And 12.6 percent of those taking the drug experienced brain swelling, compared with just 1.7 percent of those in the placebo group.
Deaths were reported at approximately the same rate in both arms of the trial of the drug.
In Alzheimer's disease, two key proteins, tau and amyloid beta, build up into tangles and plaques, known together as aggregates, which cause brain cells to die and lead to brain shrinkage.
Leqembi works by targeting amyloid.
Biogen and Eisai previously brought Aduhelm to market, but there was significant controversy over whether it worked, and its approval in 2021 led to three high-level resignations in the FDA.
An 18-month US congressional investigation said the approval process for Aduhelm was "rife with irregularities" and criticized both the agency and Biogen.
The Cambridge, Massachusetts-based Biogen set an "unjustifiably high price" for Aduhelm of $56,000 a year, the congressional report said.
Eisai said Leqembi would be priced initially at $26,500 per year.
A.Malone--AMWN